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Abstract
Chronic pain is highly prevalent worldwide and represents a significant socioeconomic and
public health burden. Several aspects of chronic pain, for example back pain and a severity-
related phenotype ‘chronic pain grade’, have been shown previously to be complex heritable
traits with a polygenic component. Additional pain-related phenotypes capturing aspects of
an individual’s overall sensitivity to experiencing and reporting chronic pain have also been
suggested as a focus for investigation. We made use of a measure of the number of sites of
chronic pain in individuals within the UK general population. This measure, termed Multisite
Chronic Pain (MCP), is a complex trait and its genetic architecture has not previously been
investigated. To address this, we carried out a large-scale genome-wide association study
(GWAS) of MCP in ~380,000 UK Biobank participants. Our findings were consistent with
MCP having a significant polygenic component, with a Single Nucleotide Polymorphism
(SNP) heritability of 10.2%. In total 76 independent lead SNPs at 39 risk loci were associ-
ated with MCP. Additional gene-level association analyses identified neurogenesis, synaptic
plasticity, nervous system development, cell-cycle progression and apoptosis genes as
enriched for genetic association with MCP. Genetic correlations were observed between
MCP and a range of psychiatric, autoimmune and anthropometric traits, including major
depressive disorder (MDD), asthma and Body Mass Index (BMI). Furthermore, in Mendelian
randomisation (MR) analyses a causal effect of MCP on MDD was observed. Additionally, a
polygenic risk score (PRS) for MCP was found to significantly predict chronic widespread
pain (pain all over the body), indicating the existence of genetic variants contributing to both
of these pain phenotypes. Overall, our findings support the proposition that chronic pain
involves a strong nervous system component with implications for our understanding of the
physiology of chronic pain. These discoveries may also inform the future development of
novel treatment approaches.
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Author summary
Chronic pain is common worldwide and imposes a significant burden from a public
health and socioeconomic perspective. The reasons why some individuals develop chronic
pain and others do not are not fully understood. In this study we searched for genetic vari-
ants associated with chronic pain in a large general-population cohort. We also assessed
how this genetic variation was correlated with a range of other diseases and traits, such as
depression and BMI, and we tested for causal relationships between depression and
chronic pain. We found that chronic pain was associated with several genes involved in
brain function and development and was correlated with mental health and autoimmune
traits (including depression, PTSD and asthma). We also found evidence for causal rela-
tionships between chronic pain and major depressive disorder. This work provides new
insights into the genetics and underlying biology of chronic pain and may help to inform
new treatment strategies.
Introduction
Chronic pain, conventionally defined as pain lasting longer than 3 months, has high global
prevalence (~30%; [1]), imposes a significant socioeconomic burden, and contributes to excess
mortality [2,3]. It is often associated with both specific and non-specific medical conditions
such as cancers, HIV/AIDS, fibromyalgia and musculoskeletal conditions [4–6], and can be
classified according to different grading systems, such as the Von Korff chronic pain grade [7].
Several aspects of chronic pain, such as chronic pain grade and back pain, have been studied
from the genetic point of view, and several have been shown to be complex traits with moder-
ate heritability [3,8]. In part due to the heterogeneity of pain assessment and pain experience,
there are very few large-scale genetic studies of chronic pain and no genome-wide significant
genetic variants have yet been identified [9,10].
Chronic pain and chronic pain disorders are often comorbid with psychiatric and neurode-
velopmental disorders, including Major Depressive Disorder (MDD) [11]. The immune and
nervous systems play a central role in chronic pain development and maintenance [12,13].
Similarly, obesity and chronic pain are often comorbid, with extrinsic factors such as sleep dis-
turbance also impacting on chronic pain [14,15]. Altered sleep quality and reduced circadian
rhythmicity are also common in those with chronic pain [16]. Chronic pain is also a common
component of many neurological diseases [17].
The relationship between injury and other peripheral insult, consequent acute pain and the
subsequent development of chronic pain has not been fully explained. Not everyone who
undergoes major surgery or is badly injured will develop chronic pain, for example [18], and
the degree of joint damage in osteoarthritis is not related to chronic pain severity [19]. Con-
versely, Complex Regional Pain Syndrome (CRPS) can be incited by minor peripheral insult
such as insertion of a needle (reviewed by Denk, McMahon and Tracey, 2014). Structural and
functional changes in the brain and spinal cord are associated with the development and main-
tenance of chronic pain, and affective brain regions are involved in chronic pain perception
(this is in contrast to acute pain and even to prolonged acute pain experience) [20–24]. It is
also unlikely that there are legitimate cut-off points or thresholds for localised and widespread
chronic pain, with pain instead existing on a “continuum of widespreadness” [25]. It may,
therefore, be more valuable and powerful to examine measures of chronic pain as complex
neuropathological traits in themselves, rather than just to study disorders and conditions with
chronic pain as a main feature or pain experienced only in specific bodily locations. Our aim
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in this study was predicated on the idea that predisposing biological processes might influence
how many sites are affected in individuals that experience any chronic pain, and we carried
out a genome-wide association study of number of chronic pain sites to look for predisposing
loci, assess the degree of genetic overlap with related traits and disorders and generate insights
into the genetic architecture of chronic pain.
Results
Genome-wide association study
To identify genetic risk loci influencing Multisite Chronic Pain (MCP), we performed a
GWAS with adjustment for age, sex and genotyping array using BOLT-LMM (see Methods).
No evidence was found for inflation of the test statistics due to hidden population stratification
(λGC = 1.26; after adjustment for sample size λGC1000 = 1.001). LD-score regression (LDSR)
analysis was consistent with a polygenic contribution to MCP (LDSR intercept = 1.0249, SE
0.0274; Fig 1) [26] and yielded a Single Nucleotide Polymorphism (SNP) heritability estimate
of 10.2%. BOLT-LMM gave a similar SNP heritability estimate (pseudo-h2 = 10.3%). In total,
1, 748 SNPs associated with MCP level at genome-wide significance (p< 5 x 10−8) were identi-
fied. Conditional analysis of the association signals at each locus revealed 76 independent
genome-wide significant lead SNPs across 39 risk loci located on chromosomes 1–11, 13–18
and 20 (Table 1). Sensitivity analysis additionally adjusting for BMI did not significantly alter
these association analysis results.
Genomic risk loci are as defined by FUMA. Genomic Locus = numeric label (1–39), rsID =
SNP rsID label, chr = chromosome, pos = position in base-pairs, Nearest Gene = nearest
mapped gene, A1 = effect allele, A2 = non-effect allele, MAF = minor allele frequency (MAF
here refers to A1 frequency as all values are< 0.5 i.e. A1 is the minor allele as well as the effect
allele), r2 = imputation r-squared value, beta = association beta value, se = standard error of
beta, P = P value of association (GWAS P value).
Post-GWAS analyses including gene expression and gene-level association testing was car-
ried out using FUMA. Gene-level association tests (MAGMA gene-based test) revealed 113
genes across 39 genomic risk loci significantly associated with MCP (S1–S3 Figs), including
genes with roles in neuronal adhesion and guidance, regulation of neural development and
neurotransmitter receptor function.
Analysis of Gene Ontology (GO) annotations revealed 3 significant categories (Table 2:
Bonferroni-corrected p< 0.05). The significant categories were enriched for terms including
neurogenesis and synaptic plasticity, DCC-mediated attractive signalling, neuron projection
guidance and central nervous system neuron differentiation, amongst others. Genes of interest
(n = 35) designated based on gene-level association tests and on annotation of genes at the
identified genomic loci (see S1 Text) are listed in S2 Table. Analysis of tissue-level expression
showed significant enrichment of brain-expressed genes, particularly in the cortex and cerebel-
lum (Fig 2),
Genetic correlations
Genetic correlations between MCP and 22 traits were estimated via LD-score regression using
ldsc [28]. The psychiatric phenotype most significantly genetically correlated with MCP was
MDD (Table 3: rg = 0.53, pFDR = 1.69e-78) while the largest significant genetic correlation coef-
ficient was for MCP and depressive symptoms (Table 3: rg = 0.59, pFDR = 6.19e-65). MCP was
also positively genetically correlated with neuroticism (Table 3: rg = 0.40), anxiety (Table 3: rg
= 0.49), schizophrenia (Table 3:rg = 0.10), cross-disorder psychiatric phenotype (Table 3: rg =
0.13) and PTSD (Table 3: rg = 0.41). Significant negative genetic correlations were observed
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between MCP and subjective well-being (Table 3: rg = -0.36), autism spectrum disorder
(Table 3: ASD; rg = -0.10) and between MCP and anorexia nervosa (Table 3: AN; rg = -0.06).
There was no significant genetic correlation between MCP and Bipolar disorder (Table 3: BD;
PFDR > 0.05). In relation to the immune-related disorders, rheumatoid arthritis (Table 3: rg =
0.16) and asthma (Table 3: rg = 0.22) were significantly positively genetically correlated with
MCP, as was primary biliary cholangitis (Table 3: rg = 0.10), while systemic lupus erythemato-
sus (SLE), ulcerative colitis and Crohn disease were not (PFDR > 0.05). BMI was significantly
genetically correlated with MCP (Table 3: rg = 0.31), while low relative amplitude, a circadian
Fig 1. Manhattan plot & QQ plot for MCP GWAS. A: SNP associations across chromosomes 1–22 are displayed. Genome-wide significance (a p value of 5
x 10−8, ~ 7.3 on the -log10 scale) is indicated by the dashed red line. B: Observed versus expected GWAS p values on the -log10 scale are shown.
https://doi.org/10.1371/journal.pgen.1008164.g001
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rhythmicity phenotype, exhibited a significant negative genetic correlation with MCP
(Table 3: rg = -0.30). There was no correlation between Parkinson disease and MCP (PFDR >
0.05). Non-significant genetic correlation results are shown in S3 Table.
Mendelian randomisation of MCP and major depressive disorder
Mendelian Randomisation with Robust Adjusted Profile Score (MR-RAPS) analysis was per-
formed to investigate causal relationships between MDD and MCP, first with MDD as the
Table 1. Genomic risk loci.
Genomic Locus rsID chr pos Nearest Gene A1 A2 MAF r2 beta se P
1 rs10888692 1 50991473 FAF1 C G 0.4301 1 -0.0143 0.0025 5.30E-09
2 rs197422 1 112000000 KCND3 C A 0.3794 1 -0.015 0.0025 2.00E-09
3 rs59898460 1 150000000 LINC00568 T C 0.4044 1 0.0169 0.0025 9.20E-12
4 rs12071912 1 243000000 RP11-261C10.3 C T 0.3163 1 -0.0153 0.0026 5.30E-09
5 rs4852567 2 80703379 CTNNA2 A G 0.2834 1 0.0149 0.0027 4.30E-08
6 rs7628207 3 49754970 RNF123:AMIGO3:GMPPB T C 0.1766 1 0.0195 0.0032 8.40E-10
7 rs28428925 3 107000000 BBX G A 0.1365 1 -0.0214 0.0035 1.40E-09
8 rs6770476 3 136000000 STAG1 C T 0.289 1 -0.0154 0.0027 9.40E-09
9 rs34811474 4 25408838 ANAPC4 G A 0.2285 1 0.0192 0.0029 2.70E-11
10 rs13135092 4 103000000 SLC39A8 A G 0.08071 1 -0.0328 0.0044 1.50E-13
11 rs13136239 4 141000000 MAML3 G A 0.3508 1 0.0141 0.0026 3.60E-08
12 rs6869446 5 65570607 RP11-305P14.1 T C 0.3861 1 -0.0144 0.0025 9.50E-09
13 rs1976423 5 104000000 RP11-6N13.1 A C 0.4968 1 -0.014 0.0024 8.20E-09
14 rs17474406 5 123000000 CEP120 G A 0.01805 1 -0.0492 0.0088 2.40E-08
15 rs1946247 5 161000000 GABRB2 T G 0.1389 1 -0.019 0.0035 4.90E-08
16 rs11751591 6 33794215 MLN G A 0.1516 1 0.0214 0.0034 2.70E-10
17 rs6907508 6 34592090 C6orf106 A G 0.1146 1 -0.0217 0.0038 1.10E-08
18 rs6926377 6 145000000 UTRN A C 0.294 1 -0.0155 0.0027 7.90E-09
19 rs10259354 7 3487414 SDK1 G A 0.2983 1 0.0147 0.0026 3.00E-08
20 rs7798894 7 21552995 SP4 A T 0.2888 1 0.0153 0.0027 1.60E-08
21 rs6966540 7 95727967 DYNC1I1 T C 0.3762 1 -0.0139 0.0025 3.30E-08
22 rs12537376 7 114000000 FOXP2 A G 0.3969 1 0.0151 0.0025 1.70E-09
23 rs11786084 8 143000000 AC138647.1 G A 0.3328 1 -0.0145 0.0026 2.30E-08
24 rs10992729 9 96181075 Y_RNA C T 0.3344 1 0.0158 0.0026 1.10E-09
25 rs6478241 9 119000000 ASTN2 A G 0.365 1 0.0149 0.0025 3.10E-09
26 9:140251458_G_A 9 140000000 EXD3 G A 0.123 1 -0.0277 0.0037 5.30E-14
27 rs2183271 10 21957229 MLLT10 T C 0.3578 1 -0.014 0.0025 3.10E-08
28 rs11599236 10 106000000 SORCS3 T C 0.4058 1 0.0138 0.0025 3.30E-08
29 rs12765185 10 135000000 KNDC1 T A 0.2669 1 -0.0151 0.0027 3.90E-08
30 rs61883178 11 16317779 SOX6 C A 0.1696 1 -0.0208 0.0033 2.00E-10
31 rs1443914 13 53917230 AL450423.1 T C 0.475 1 0.0162 0.0024 2.80E-11
32 rs12435797 14 73797669 NUMB G T 0.1859 1 -0.0173 0.0031 3.70E-08
33 rs2006281 14 104000000 CTD-2134A5.4 C T 0.4981 1 0.0135 0.0024 3.40E-08
34 rs2386584 15 91539572 PRC1 T G 0.3835 1 -0.0166 0.0025 2.80E-11
35 rs285026 16 77100089 MON1B G T 0.4297 1 -0.0138 0.0025 1.90E-08
36 rs11871043 17 43172849 NMT1 T C 0.4213 1 0.0149 0.0025 1.70E-09
37 rs11079993 17 50301552 snoZ178 G T 0.3825 1 -0.0173 0.0025 5.70E-12
38 rs62098013 18 50863861 DCC G A 0.3631 1 -0.0169 0.0026 4.00E-11
39 rs2424248 20 19650324 SLC24A3 G A 0.1255 1 0.023 0.0037 3.70E-10
https://doi.org/10.1371/journal.pgen.1008164.t001
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exposure and MCP as the outcome. QQ plots, leave-one out versus t-value plots (S4 Fig) and
Anderson-Darling/ Shapiro-Wilk test p values indicated that models without dispersion were
best-fitting (S4 Table rows 1–3, pAD > 0.05, pSW > 0.05). Effects of outliers (idiosyncratic plei-
otropy) are not ameliorated in models with dispersion despite robust regression (S4D, S4E and
S4F Fig right-hand panels). The model allowing the greatest amelioration of pleiotropy is one
without over-dispersion and with a Tukey loss function (S4 Table: row 3, S4C Fig). This indi-
cates idiosyncratic pleiotropy (pleiotropy in some but not all instruments), i.e. that a subset of
instruments may affect MCP through pathways other than via MDD (the exposure). The
causal effect of MDD on MCP is positive and significant at beta = 0.019 and p = 0.0006, but
the diagnostic plots show a ‘swapping’ of sign for the causal estimate (S4 Fig), suggesting that
there is not a truly significant causal effect of MDD on MCP.
MR-RAPS analyses were then carried out with MCP as the exposure and MDD as the out-
come. Models with dispersion are a better fit than those without (S5A, S5B, S5C vs S5D, S5E
and S5F Fig, S5 Table: rows 4–6, pAD > 0.05, pSW > 0.05, pτ<< 0.05). This indicates that
effectively all instruments are pleiotropic (affecting MDD through pathways other than via
MCP). The causal effect of MCP on MDD is positive and significant at beta = 0.16 and
p = 0.047.
Overall, this analysis suggests a causal effect of MCP on MDD.
Relationship between multisite chronic pain and chronic widespread pain
Polygenic Risk Score (PRS) analyses were carried out to examine the relationship between
MCP and chronic widespread pain in UK Biobank. Increasing MCP PRS value was signifi-
cantly associated with having chronic pain all over the body (S6 Table: p = 1.45 x 10−109), with
each per-standard-deviation increase in PRS associated with a 63% increase in the odds of hav-
ing chronic widespread pain.
A secondary GWAS of chronic widespread pain (CWP) was carried out, the results from
which were used in LD score regression analysis to determine the genetic correlation between
CWP and MCP. This was found to be large (rg = 0.83) and significant (p = 2.45 x 10
−54). A
lookup analysis was also carried out using the CWP GWAS summary statistics, and>90% of
SNPs showed consistent direction of effect between MCP and CWP (S7 Table). In addition, a
paired t-test of MCP versus CWP effect values showed that they are not significantly different
overall (t = -1.82, p = 0.07).
LocusZoom plots
LocusZoom plots for independent, genome-wide significant loci, calculated according to the
supplementary methods detailed in S1 Text, are shown in S6 Fig.
Table 2. GO annotations.
Gene Set N genes Beta SE SE P Pbon
GO_bp:go_neuron_projection_guidance 195 0.335 0.0341 0.0711 1.25E-06 0.013361
Curated_gene_sets:reactome_dcc_mediated_attractive_signaling 13 1.45 0.0381 0.313 1.94E-06 0.020616
GO_bp:go_central_nervous_system_neuron_differentiation 158 0.362 0.0331 0.0811 4.05E-06 0.043154
Significant GO annotations (ranked by p value) are shown. Beta = beta coefficient value from the FUMA MAGMA gene-set analyses for this Gene Ontology (GO) gene
set, SE = standard error of beta, Pbon = Bonferroni-corrected p value. ‘GO_bp’ and ‘Curated_gene_sets’ refers to Gene Ontology categories biological processes and
curated gene sets respectively [27].
https://doi.org/10.1371/journal.pgen.1008164.t002
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Discussion
We identified 76 independent genome-wide significant SNPs associated with MCP across 39
loci. The genes of interest had diverse functions, but many were implicated in nervous-system
development, neural connectivity and neurogenesis.
Genes of interest identified in GWAS of MCP
Potentially interesting genes included DCC (Deleted in Colorectal Cancer a.k.a. DCC netrin 1
receptor) which encodes DCC, the receptor for the guidance cue netrin 1, which is important
Fig 2. A) GteX Output–General Tissues. B) GteX Output–Detailed Tissues. Fig 2A and 2B. GTeX output–General Tissues and Detailed
Tissues.
https://doi.org/10.1371/journal.pgen.1008164.g002
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for nervous-system development [29]. SDK1 (Sidekick Cell Adhesion molecule 1) is implicated
in HIV-related nephropathy in humans [30] and synaptic connectivity in vertebrates [31], and
ASTN2 (Astrotactin 2) is involved in glial-guided neuronal migration during development of
cortical mammalian brain regions [32].
MAML3 (Mastermind-Like Transcriptional coactivator 3) is a key component of the Notch
signalling pathway [33,34], which regulates development and maintenance of a range of cell
and tissue types in metazoans. During neurogenesis in development the inhibition of Notch
signalling by Numb promotes neural differentiation [35]. Numb is encoded by NUMB (Endo-
cytic Adaptor Protein), which was also associated with MCP. In the adult brain Notch signal-
ling has been implicated in CNS plasticity across the lifespan [35].
CTNNA2 (Catenin Alpha 2) encodes a protein involved in cell-cell adhesion [36], found to
play a role in synapse morphogenesis and plasticity [37,38]. CEP120 (Centrosomal Protein
120) encodes Cep120, vital for Interkinetic Nuclear Migration (INM) in neural progenitor
cells of the cortex [39]. KNDC1 (Kinase Non-Catalytic C-Lobe Domain Containing 1) encodes
v-KIND in mice, linked to neural morphogenesis in the cortex [40], and KNDC1 in humans,
linked to neuronal dendrite development and cell senescence [41]. SOX6 (SRY-Box 6) is part
of the Sox gene family, first characterised in mouse and human testis-determining gene Sry
[42] and encoding transcription factors involved in a range of developmental processes
[43,44]. SOX6 may be involved in development of skeletal muscle [43], maintenance of brain
neural stem cells [45] and cortical interneuron development [46], and variants in this gene
have been associated with bone mineral density in both white and Chinese populations [47].
CA10 (Carbonic Anhydrase 10) is predominantly expressed in the CNS, encoding a protein
involved in development and maintenance of synapses [48]. DYNC1I1 (Dynein Cytoplasmic 1
Intermediate Chain 1) encodes a subunit of cytoplasmic dynein, a motor protein which plays a
role in cargo transport along microtubules, including in the function of neuronal cells [49].
UTRN (Utrophin) is a homologue of Duchenne Muscular Dystrophy gene (DMD), encoding
utrophin protein which is localised to the neuromuscular junction (NMJ) [50]. Utrophin has
Table 3. Genetic correlations between MCP and multiple traits.
Trait rg se z h2 Ph2 (fdr) source PMID Category p P (fdr-corrected)
MDD 0.53 0.03 18.92 0.077 1.25E-47 PGC 29700475 psychiatric 7.68E-80 1.69E-78
Depressive symptoms 0.59 0.03 17.16 0.047 6.87E-29 ld_hub 27089181 psychiatric 5.63E-66 6.19E-65
BMI 0.31 0.02 15.69 0.138 5.42E-59 GIANT consortium 25673413 anthropometric 1.90E-55 1.39E-54
Neuroticism 0.4 0.03 11.9 0.089 3.66E-26 ld_hub 27089181 personality 1.24E-32 6.82E-32
Subjective well being -0.36 0.04 -8.94 0.025 2.77E-32 ld_hub 27089181 psychiatric 3.78E-19 1.66E-18
Low Relative Amplitude -0.3 0.05 -6.37 0.053 3.03E-13 In-house analysis 30120083 circadian 1.91E-10 7.00E-10
Rheumatoid Arthritis 0.16 0.03 4.7 0.160 7.41E-08 ld_hub 24390342 autoimmune 2.64E-06 8.30E-06
Anxiety (Case-Control) 0.49 0.11 4.53 0.081 0.00405 PGC 26754954 psychiatric 5.91E-06 1.63E-05
Schizophrenia 0.1 0.03 4.08 0.443 6.56E-79 PGC 25056061 psychiatric 4.50E-05 1.10E-04
Asthma 0.22 0.06 3.63 0.123 3.53E-06 ld_hub 17611496 autoimmune 3.00E-04 6.60E-04
PGC cross-disorder analysis 0.13 0.04 3.54 0.172 7.89E-36 ld_hub 23453885 psychiatric 4.00E-04 8.00E-04
PTSD (European Ancestry) 0.41 0.12 3.28 0.097 0.030855 PGC 28439101 psychiatric 0.001047 1.92E-03
Autism spectrum disorder -0.1 0.04 -2.22 0.451 9.38E-17 ld_hub NA psychiatric 0.026 0.0443
Primary biliary cirrhosis 0.1 0.04 2.17 0.376 1.11E-08 ld_hub 26394269 autoimmune 0.03 0.047
Anorexia Nervosa -0.06 0.03 -2.14 0.556 2.18E-63 ld_hub 24514567 psychiatric 0.032 0.0471
rg = genetic correlation coefficient value, se = standard error of correlation value, z = z value, h2 = SNP-heritability value, ph2(fdr) = p value (FDR-corrected) for SNP-
heritability, source = source of GWAS summary statistics, PMID = PubMed ID of associated paper (if applicable), p = p value for genetic correlation coefficient, p(fdr) =
FDR-corrected p value for genetic correlation coefficient.
https://doi.org/10.1371/journal.pgen.1008164.t003
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also been implicated in neutrophil activation [51], dystrophin-associated-protein (DPC)-like
complex formation in the brain [52], and is expressed during early foetal brain development in
neurons and astrocytes [53].
FOXP2 encodes a member of the FOX family of transcription factors, which are thought to
regulate expression of hundreds of genes in both adult and foetal tissue, including the brain
[54]. These transcription factors may play an important role in brain development, neurogen-
esis, signal transmission and synaptic plasticity [55]. FOXP2 is essential for normal speech and
language development [56]. GABRB2 encodes a GABA (gamma-aminobutyric acid) type A
receptor beta subunit. These pentameric chloride channels mediate fast inhibitory synaptic
transmission and are extremely important for network function in many brain regions, with
the b2 subunit forming part of the most widely expressed receptor across the mammalian
brain [57,58].
Another group of genes associated with MCP were linked to cell-cycle progression, DNA
replication and apoptosis such as EXD3 (Exonuclease 3’-5’ Domain Containing 3), which
encodes a protein involved in maintaining DNA fidelity during replication (‘proof-reading’)
[59]. BBX (HMG-Box Containing protein 2) encodes an HMG (high mobility group) box-con-
taining protein necessary for cell-cycle progression from G1 to S phase [60]. STAG1 (Cohesin
Subunit SA-1) encodes a cohesin-complex component–cohesin ensures sister chromatids are
organised together until prometaphase [61–63]. ANAPC4 (Anaphase Promoting Complex
Subunit 4) encodes a protein making up the anaphase promoting complex (APC), an essential
ubiquitin ligase for eukaryotic cell-cycle progression [64]. PRC1 (Protein Regulator of Cytoki-
nesis 1) is involved in the regulation of cytokinesis [65], the final stage of the cell cycle. Y RNA
(Small Non-Coding RNA, Ro-Associated Y3) encodes a small non-coding Y RNA. These
RNAs have been implicated in a wide range of processes, including cell stress response, DNA
replication initiation and RNA stability [66]. FAM120A (Oxidative Stress-Associated Src Acti-
vator) encodes an RNA-binding protein which regulated Src-kinase activity during oxidative
stress-induced apoptosis [67]. The protein encoded by MON1B (MON1 Homolog B, Secretory
Trafficking Associated) is necessary for clearance of cell ‘corpses’ following apoptosis, with
defects associated with autoimmune pathology [68]. FAF1 (Fas Associated Factor 1) encodes a
protein which binds the Fas antigen to initiate or facilitate apoptosis, amongst a wide range of
other biological processes (including neuronal cell survival) [69].
Several MCP associated genes have been previously implicated in diseases such as Brugada
Syndrome 9 and Spinal ataxia 19 & 22 (KCND3) [70–72], Systemic lupus erythematosus (SLE)
(Y RNAs) [66], Joubert syndrome 31 and short-rib thoracic dysplasia 13 (CEP120) [73],
Amyotrophic lateral sclerosis (ALS) (FAF1) [74], Urbach-Wiethe disease (ECM1) [75,76],
mental retardation and other cohesinopathies such as Cornelia de Lange Syndrome (STAG1)
[77,78], split hand/ split foot malformation (DYNC1I1) [79,80], and a wide range of cancers
(PRC1) [81]. Other disorders found to involve MCP-related genes include schizophrenia
(FOXP2 and GABRB2) [82–88], intellectual disability and epilepsy (GABRB2) [89], and neuro-
leptic-induced tardive dyskinesia (GABRB2) [90].
Several GWASs of chronic pain at specific body sites, of specific pain types such as neuro-
pathic pain, and of diseases and disorders where chronic pain is a defining symptom, have
been carried out previously (reviewed by [10], [91]). DCC and SOX5 (which jointly functions
with SOX6 in chondrogenesis) have been associated with chronic back pain [92], GABRB3
(encoding one of three beta subunits of the GABA A receptor along with GABRB2) has been
associated with migraine and fibromyalgia [10], and ASTN2 and SLC24A3 have been associ-
ated with migraine [10,93]
Overall, this indicated that MCP, a chronic pain phenotype, involves structural and func-
tional changes to the brain, including impact upon neurogenesis and synaptic plasticity both
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during development and in adulthood. Also implicated was regulation of cell-cycle progres-
sion and apoptosis. This is also supported by GO categories DCC-mediated attractive signal-
ling, neuron projection guidance and CNS neuron differentiation being significantly
associated with MCP. There was also evidence of pleiotropy, with genes associated with a
range of neurodegenerative, psychiatric, developmental and autoimmune disease traits, as well
as being associated with MCP.
Genetic correlations
Chronic pain and chronic pain disorders are often comorbid with psychiatric and neurodeve-
lopmental disorders [11]. This has been observed for Major Depressive Disorder (MDD)
[8,94], post-traumatic stress-disorder (PTSD) [95–99], schizophrenia [100–102] and bipolar
disorder (BD) [94,103]. There are also reported differences in the perception of pain and inter-
oception (sensing and integration of bodily signals) for people with schizophrenia [104,105],
anorexia nervosa (AN) [106–108] and autism spectrum disorders (ASD) [109,110], with some
evidence of an increase in pain thresholds for AN and ASD.
There is significant cross-talk between the immune system and nervous system in nocicep-
tion and sensitisation leading to chronic pain [12,13], and many autoimmune disorders cause
or have been associated with chronic pain including neuroinflammation implicated in devel-
opment of neuropathic pain [111].
Similarly, obesity and chronic pain are often comorbid, with extrinstic factors such as
MDD and sleep disturbance also impacting on chronic pain [14,15]. Obesity and related
chronic inflammation may affect chronic pain [112], and adipose tissue is metabolically active
in ways that can affect pain perception and inflammation [113–115].
Sleep changes and loss of circadian rhythm is common in those with chronic pain [16], and
myriad chronic diseases, including chronic pain, have shown diurnal patterns in symptom
severity, intensity and mortality [116,117]. Chronic pain is also a common component of
many neurological diseases, particularly Parkinson’s disease [17], and disorders such as Multi-
ple Sclerosis and migraines are considered neurological in nature.
MCP showed moderate positive genetic correlation with a range of psychiatric disorders
including MDD, SCZ, and PTSD, along with traits anxiety and neuroticism. The magnitude of
genetic correlation between MCP and MDD was similar to that shown for von Korff chronic
pain grade (a chronic pain phenotype) and MDD by McIntosh et al via a mixed-modelling
approach (ρ = 0.53) [8]. This is in line with previous observations of association and indicates
that shared genetic risk factors exist between MCP and a range of psychiatric disorders, most
notably MDD, and that the genetic correlation between MCP and MDD matches with that
between MDD and von Korff CPG, a validated chronic-pain questionnaire-derived phenotype
[7].
Autoimmune disorders rheumatoid arthritis, asthma and primary biliary cholangitis
showed positive genetic correlation with MCP. However, gastrointestinal autoimmune disor-
ders UC, IBD and Crohn’s Disease did not. This suggests separate genetic variation and mech-
anisms underlying chronic pain associated with these autoimmune disorders compared to
those outwith the digestive system. Pain related to inflammatory bowel diseases may represent
something less ‘chronic’ and more ‘on-going acute’, as stricture, abscesses and partial or com-
plete obstruction of the small bowel result in pain [118]. Structural and functional brain
changes associated with the transition to chronic pain may also play a less central role in gas-
trointestinal autoimmune disorder-associated pain, due to potential for the enteric nervous
system (ENS) to act independently from the CNS, and the role of the gut-brain axis (GBA)
[119,120].
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There was significant negative genetic correlation between low relative amplitude, a circa-
dian rhythmicity phenotype indicating poor rhythmicity [121]. Opposing direction of effect of
genetic variants on MCP versus low RA may mean that insomnia and other sleep difficulties
(for which low RA represents a proxy phenotype) associated with MCP are due to environ-
mental and lifestyle factors related to chronic pain, rather than shared genetic factors predis-
posing to increased risk for both traits. There was also significant negative genetic correlation
between MCP and both AN and ASD, which may be linked to changes in interoception and
atypical pain experience seen in individuals with these conditions [106–110], and may suggest
a genetic basis for increased pain thresholds.
SNP heritability of MCP
LDSR analyses gave a heritability estimate of 10.2% for MCP, lower than the pseudo-h2 esti-
mate of 10.3% given by BOLT-LMM. this suggests SNP-heritability (h2) of MCP to be
roughly-10%, slightly lower than an estimate of ‘any chronic pain’ of 16%, and markedly lower
than a heritability estimate of 30% for ‘severe chronic pain’ derived from a pedigree-based
analyses [3].
Causal associations between MDD and MCP
Mendelian randomisation analyses indicated a causal effect of MCP on MDD, with widespread
pleiotropy and a less significant causal estimate value for MCP as the exposure–this suggests
most instruments for MCP are pleiotropic, affecting MDD through pathways other than
directly through MCP. In contrast, only a small subset of instruments for MDD as the expo-
sure were found to be pleiotropic.
Relationship between MCP and CWP
It has been argued that CWP and other clinical syndromes involving chronic pain all over the
body represent the upper end of a spectrum of centralisation of pain, or the extreme of a
chronic pain state [122]. It has also been argued that there are not “natural cut-off points”
when it comes to chronic widespread pain versus localised chronic pain [25]. In support of
this view, the MCP PRS was significantly associated with increased odds of having chronic
pain all over the body/ CWP, suggesting that chronic widespread pain may in fact represent
the upper end of a spectrum of ‘widespreadness’ of chronic pain, as previously suggested
[25,122], and that there are likely to be genetic variants that predispose both to MCP and to
CWP.
Conclusions & limitations
Multisite chronic pain (MCP), a chronic pain phenotype defined as the number of sites at
which chronic pain is experienced, is a complex trait with moderate heritability. To date, this
study represents the largest GWAS of any chronic pain phenotype and elucidates potential
underlying mechanisms of chronic pain development. Substantial genetic correlations with a
range of psychiatric, personality, autoimmune, anthropometric and circadian traits were
identified.
The genes potentially associated with MCP implicated neurogenesis, neuronal development
and neural connectivity, along with cell-cycle and apoptotic processes, and expression was pri-
marily within brain tissues. This is in line with theories of functional and structural changes to
the brain contributing to development of chronic pain [21,24,123–125], and may also explain
the genetic correlations observed. A causal effect of MCP on MDD was identified.
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Although the phenotype was based on self-report, this study was very large in size and so
likely had sufficient power to detect genetic variation associated with MCP. Replication of SNP
associations was not possible due to the nature of chronic pain phenotyping and available
cohort sizes, but several genes significantly associated with MCP have been previously associ-
ated with chronic pain conditions including chronic back pain, migraine and fibromyalgia,
and genetic risk for MCP was found to be significantly associated with chronic widespread
pain.
Methods
We carried out a GWAS of Multisite Chronic Pain (MCP), a derived chronic pain phenotype,
in 387,649 UK Biobank participants (Table 4). UK Biobank is a general-population cohort of
roughly 0.5 million participants aged 40–79 recruited across the UK between 2006 and 2010.
Details on phenotyping, follow-up and genotyping have been described in detail elsewhere
[126].
Phenotype definition and GWAS
During the baseline investigations, UK Biobank participants were asked via a touchscreen
questionnaire about “pain types experienced in the last month” (field ID 6159), with possible
answers: ‘None of the above’; ‘Prefer not to answer’; pain at seven different body sites (head,
face, neck/shoulder, back, stomach/abdomen, hip, knee); or ‘all over the body’. The seven indi-
vidual body-site pain options were not mutually exclusive and participants could choose as
many as they felt appropriate. Where patients reported recent pain at one or more body sites,
or all over the body, they were additionally asked (category ID 100048) whether this pain had
lasted for 3 months or longer. Those who chose ‘all over the body’ could not also select from
the seven individual body sites.
Multisite Chronic Pain (MCP) was defined as the sum of body sites at which chronic pain
(at least 3 months duration) was recorded: 0 to 7 sites. Those who answered that they had
chronic pain ‘all over the body’ were excluded from the GWAS as there is some evidence that
this phenotype relating to widespread pain can be substantially different from more localised
chronic pain [94] and should not, therefore, be considered a logical extension of the multisite
scale. 10,000 randomly-selected individuals reporting no chronic pain were excluded from the
GWAS to use as controls in subsequent polygenic risk score (PRS) analyses.
SNPs with an imputation quality score of less than 0.3, Minor Allele Frequency (MAF) <
0.01 and Hardy-Weinberg equilibrium (HWE) test p< 10−6 were removed from the analyses.
Participants whose self-reported sex did not match their genetically-determined sex, those
Table 4. Demographics of those included in BOLT-LMM GWAS of MCP.
chronic pain sites male (N) female (N) male (%) female (%) age (mean) total (N) total (%)
0 105474 113148 48.2 51.8 56.71 218622 56.40
1 42734 49984 46.1 53.9 57.03 92718 23.92
2 18612 26000 41.7 58.3 57.29 44612 11.51
3 7771 12376 38.6 61.4 57.65 20147 5.20
4 2970 5319 35.8 64.2 57.48 8289 2.14
5 780 1723 31.2 68.8 56.53 2503 0.65
6 181 471 27.8 72.2 56.20 652 0.17
7 34 72 32.1 67.9 56.17 106 0.03
total 178556 209093 NA NA 56.91 387649 NA
https://doi.org/10.1371/journal.pgen.1008164.t004
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who had putative sex-chromosome aneuploidy, those considered outliers due to missing het-
erozygosity, those with more than 10% missing genetic data and those who were not of self-
reported white British ancestry were excluded from analyses.
An autosomal GWAS was run using BOLT-LMM [127], with the outcome variable, MCP,
modelled as a linear quantitative trait under an infinitesimal model, and the model adjusted
for age, sex and chip (genotyping array). Related individuals are included and accounted for,
as are any population stratification effects, via use of a genetic relatedness matrix as part of the
BOLT-LMM analysis [127]. The SNP-level summary statistics from the GWAS output were
analysed using FUMA [128], which implements a number of the functions from MAGMA
(gene-based association testing, gene-set analyses) [129]. Tissue expression (GTEx) analysis
[130] and Gene Ontology [27] and ANNOVAR [131] annotation analysis with default settings
was used to characterise lead SNPs further. LocusZoom [132] was used to plot association
results at higher resolution (N = 47) (S1 Text). Genomic risk loci were identified using the def-
inition deployed by FUMA [128].
Genetic correlation analysis
Genetic correlations between MCP and 22 complex traits selected on the basis of prior pheno-
typic association evidence were calculated using linkage disequilibrium score regression
(LDSR) analyses [28], implemented either using the ‘ldsc’ package [28] and downloaded pub-
licly-available summary statistics and summary statistics from in-house analyses or using LD
Hub [133]. LD Hub datasets from the categories Psychiatric, Personality, Autoimmune and
Neurological were selected and datasets with the attached warning note ‘Caution: using this
data may yield less robust results due to minor departure from LD structure’ were excluded
from the analyses. Where multiple GWAS datasets were available for the same trait, the one
with the largest sample size and/or European ancestry was retained with priority given to
European ancestry.
Mendelian randomisation analysis of MCP and major depressive disorder
Mendelian randomisation analysis was carried out with MR-RAPS (MR-Robust Adjusted Pro-
file Score; [134] using the R package ‘mr-raps’. This method is appropriate when doing MR
analysis of phenotypes that are moderately genetically correlated and likely to share some
pleiotropic risk loci. MDD was chosen for MR analysis as this disorder represents an impor-
tant and common comorbidity with chronic pain [2,8,135]. Summary statistics from the most
recent MDD GWAS meta-analysis [136], with UK Biobank and 23andMe results removed,
were harmonised with MCP GWAS summary statistics following guidelines [137] as closely as
possible with the available data. Bi-allelic SNPs shared between the two datasets were identified
and harmonised (by ‘flipping’) with respect to the strand used to designate alleles. Reciprocal
MR analysis was carried out using subsets of SNPs associated with each of the exposure traits
(MCP and MDD) at p< 10−5. This threshold is an order of magnitude lower than suggested
as part of the MR-RAPS method [134] and was chosen in order to attempt to account for ‘win-
ner’s curse’, as independently selecting and then testing association for instruments in separate
GWAS datasets was not possible in this study. The harmonisation process also involved ensur-
ing that the effect allele was trait-increasing in the exposure trait, and that the effect allele
matched between the exposure and the outcome. These selected subsets of variants were then
LD-pruned at a threshold of r2 < 0.01 using command-line PLINK using ‘indep-pairwise’ with
a 50-SNP window and sliding window of 5 SNPs [138]. This resulted in a set of 200 instru-
ments for MCP as the exposure, and a set of 99 instruments for MDD as the exposure.
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PRS prediction of chronic widespread pain
Those who reported chronic pain all over the body were excluded from the MCP GWAS anal-
yses above. This is because chronic pain all over the body, taken as a proxy for chronic wide-
spread pain (CWP), may be a different clinical syndrome from more localised chronic pain,
and does not necessarily directly reflect chronic pain at 7 bodily sites. To investigate the rela-
tionship between CWP and MCP, a polygenic risk score (PRS) approach was taken.
A PRS was constructed for MCP in individuals who reported chronic pain all over the body
(n = 6,815; these individuals had all been excluded from the MCP GWAS), and in controls
(n = 10,000 individuals reporting no chronic pain at any site, also excluded from the MCP
GWAS). The PRS was calculated using SNPs associated with MCP at p < 0.01, weighting by
MCP GWAS effect size (GWAS β) for each SNP. A standardised PRS (based on Z-scores) was
used in all analyses, constructed by dividing the calculated PRS by its standard deviation across
all samples. The ability of the standardised PRS to predict chronic widespread pain status was
investigated in logistic regression models adjusted for age, sex, genotyping array and the first 8
genetic principal components.
Individual-level data are available via application to UK Biobank. Multisite chronic pain
GWAS summary statistics are available via contacting the authors and will be submitted to UK
Biobank for publication at their website.
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